INTRODUCTION: Chronic venous disease (CVD) is a common condition associated with valvular dysfunction, venous hypertension and endothelial inflammation. Sulodexide facilitates the healing of venous ulcers and is frequently used in patients with CVD without ulcer. This review assessed the efficacy and safety of sulodexide for treatment of signs and symptoms of lower extremity CVD. METHODS: We searched MEDLINE, EMBASE, CINAHL and AMED as well as the Cochrane Central Register of Controlled Trials and the World Health Organisation (WHO) International Clinical Trials Registry Platform Search Portal. We also manually searched potentially relevant journals, conference proceedings and journal supplements. Any study monitoring any effect of sulodexide in patients with CVD at any stage of the disease, classified or non-classified, was considered. Treatment effects were estimated using standardised mean differences (SMDs), mean differences (MDs) and risk ratios (RRs), as appropriate. We calculated 95% confidence intervals (CIs) and heterogeneity (Q, tau and I2). RESULTS: The search found 64 studies, but only 23 provided data on 7153 participants (mean age 55 years; 68% female). The 13 studies providing extractable quantitative information included 1901 participants (mean age 55.2 years; 65% female). Sulodexide decreased the intensity of pain, cramps, heaviness, oedema and total symptom score and reduced inflammatory mediators in patients with CVD. The risk of adverse events (AEs) was not different between sulodexide and placebo or heparan sulphate (RR 1.31, 95% CI 0.74-2.32; I2 = 0%; 270 participants). The overall risk of AEs with sulodexide was low: 3% (95% CI 1-4%) estimated from 3656 participants. CONCLUSION: Sulodexide was found to have a beneficial venoactive effect on the major signs and symptoms of CVD such as pain, cramps, heaviness and oedema without increasing the risk of AEs. It is also likely to exert a systemic effect on the course of CVD by interfering with inflammatory chemokines.

Angiologická Ambulance Hodonín Czech Republic

Department of Pharmaceutical Sciences School of Specialisation in Hospital Pharmacy University of Milan Milano Italy

Zobrazit více v PubMed

Castro-Ferreira R, Cardoso R, Leite-Moreira A, Mansilha A. The role of endothelial dysfunction and inflammation in chronic venous disease. Ann Vasc Surg. 2018;46:380–393. PubMed

Bergan JJ, Schmid-Schonbein GW, Smith PD, Nicolaides AN, Boisseau MR, Eklof B. Chronic venous disease. N Engl J Med. 2006;355:488–498. PubMed

Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34:428–436. PubMed

Criqui MH, Jamosmos M, Fronek A, et al. Chronic venous disease in an ethnically diverse population: the San Diego Population Study. Am J Epidemiol. 2003;158:448–456. PubMed PMC

Meissner MH, Gloviczki P, Bergan J, et al. Primary chronic venous disorders. J Vasc Surg. 2007;46(Suppl S):54S–67S. PubMed

Meissner MH, Eklof B, Smith PC, et al. Secondary chronic venous disorders. J Vasc Surg. 2007;46(Suppl S):68S–83S. PubMed

Kurz X, Kahn SR, Abenhaim L, et al. Chronic venous disorders of the leg: epidemiology, outcomes, diagnosis and management. Summary of an evidence-based report of the VEINES task force. Venous Insufficiency Epidemiologic and Economic Studies. Int Angiol. 1999;18:83–102. PubMed

Labropoulos N, Gasparis AP, Pefanis D, Leon LR, Jr, Tassiopoulos AK. Secondary chronic venous disease progresses faster than primary. J Vasc Surg. 2009;49:704–710. PubMed

Nicolaides AN, Allegra C, Bergan J, et al. Management of chronic venous disorders of the lower limbs: guidelines according to scientific evidence. Int Angiol. 2008;27:1–59. PubMed

Marinel.lo Roura J. [Etiology of CVI: Primary venous insufficiency. In Marinel.lo Roura, J ed. Ulcers of the Lower Limbs]. Barcelona: Editorial Glosa 2005:115–7. (Book in Spanish). https://editorialglosa.es

Lim CS, Davies AH. Pathogenesis of primary varicose veins. Br J Surg. 2009;96:1231–1242. PubMed

Mannello F, Ligi D, Raffetto JD. Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic venous disease. Int Angiol. 2014;33:236–242. PubMed

Andreozzi GM. Sulodexide in the treatment of chronic venous disease. Am J Cardiovasc Drugs. 2012;12:73–81. PubMed

Kahn SR, Mathes BM. Post-thrombotic (postphlebitic) syndrome. In: Collins KA (Ed.), UpToDate. Waltham, MA: UpToDate Inc. Available from from https://www.uptodate.com/contents/post-thrombotic-postphlebitic-syndrome Accessed 25 Apr 2019.

Eklof B, Rutherford RB, Bergan JJ, et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg. 2004;40:1248–1252. PubMed

Vasquez MA, Rabe E, McLafferty RB, et al. Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. J Vasc Surg. 2010;52:1387–1396. PubMed

Marston WA, Vasquez MA, Lurie F, et al. Multicenter assessment of the repeatability and reproducibility of the revised Venous Clinical Severity Score (rVCSS) J Vasc Surg Venous Lymphat Disord. 2013;1:219–224. PubMed

Mathes BM. Clinical manifestations of lower extremity chronic venous disease. In: Collins KA (Ed.), UpToDate. Waltham, MA: UpToDate Inc. 2019; Available from https://www.uptodate.com/contents/clinical-manifestations-of-lower-extremity-chronic-venous-disease Accesed 24 Apr 2019.

Perrin M, Eklof B, VANR A, et al. Venous symptoms: the SYM vein consensus statement developed under the auspices of the European Venous Forum. Int Angiol. 2016;35:374–398. PubMed

Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016;4:CD003229. PubMed PMC

Gloviczki P, Comerota AJ, Dalsing MC, et al. The care of patients with varicose veins and associated chronic venous diseases: clinical practice guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2011;53:2S–48S. PubMed

Myers K, Roberts S. ACP consensus on cyanoacrylate adhesive closure. Phlebolymphology. 2018;25:103.

Jull AB, Mitchell N, Arroll J, et al. Factors influencing concordance with compression stockings after venous leg ulcer healing. J Wound Care. 2004;13:90–92. PubMed

Raju S, Hollis K, Neglen P. Use of compression stockings in chronic venous disease: patient compliance and efficacy. Ann Vasc Surg. 2007;21:790–795. PubMed

Renner R, Gebhardt C, Simon JC. Compliance to compression therapy in patients with existing venous leg ulcers. Results of a cross-sectional study. Med Klin (Munich). 2010;105:1–6. PubMed

Ayala A, Guerra JD, Ulloa JH, Kabnick L. Compliance with compression therapy in primary chronic venous disease: results from a tropical country. Phlebology. 2019;34:272–277. PubMed

Kankam HKN, Lim CS, Fiorentino F, Davies AH, Gohel MS. A summation analysis of compliance and complications of compression hosiery for patients with chronic venous disease or post-thrombotic syndrome. Eur J Vasc Endovasc Surg. 2018;55:406–416. PubMed

Branisteanu DE. Assessing compliance with nonoperative treatments of chronic venous disorders: the VEIN Act Program in Romania. Medicographia. 2016;38:175–180.

Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2013;8:49–65. PubMed PMC

Gaddi A, Galetti C, Illuminati B, Nascetti S. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res. 1996;24:389–406. PubMed

Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J. 2002;23:1057–1065. PubMed

Condorelli M, Chiariello M, Dagianti A, et al. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol. 1994;23:27–34. PubMed

Errichi BM, Cesarone MR, Belcaro G, et al. Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. Angiology. 2004;55:243–249. PubMed

Cirujeda JL, Granado PC. A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology. 2006;57:53–64. PubMed

Andreozzi GM, Bignamini AA, Davi G, et al. Sulodexide for the prevention of recurrent venous thromboembolism: The Sulodexide In Secondary Prevention Of Recurrent Deep Vein Thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial. Circulation. 2015;132:1891–1897. PubMed PMC

Cospite M, Milio G, Ferrara F, Cospite V, Palazzini E. Haemodynamic effects of sulodexide in post-thrombophlebitic syndrome. Acta Ther. 1992;18:149–161.

Luzzi R, Belcaro G, Dugall M, et al. The efficacy of sulodexide in the prevention of postthrombotic syndrome. Clin Appl Thromb Hemost. 2014;20:594–599. PubMed

Adiguzel C, Iqbal O, Hoppensteadt D, et al. Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide. Clin Appl Thromb Hemost. 2009;15:501–511. PubMed

Ligi D, Mosti G, Croce L, Raffetto JD, Mannello F. Chronic venous disease—part I: inflammatory biomarkers in wound healing. Biochim Biophys Acta. 2016;1862:1964–1974. PubMed

Mannello F, Ligi D, Canale M, Raffetto JD. Sulodexide down-regulates the release of cytokines, chemokines, and leukocyte colony stimulating factors from human macrophages: role of glycosaminoglycans in inflammatory pathways of chronic venous disease. Curr Vasc Pharmacol. 2014;12:173–185. PubMed

Ligi D, Mosti G, Croce L, Raffetto JD, Mannello F. Chronic venous disease—part II: proteolytic biomarkers in wound healing. Biochim Biophys Acta. 2016;1862:1900–1908. PubMed

Broekhuizen LN, Lemkes BA, Mooij HL, et al. Effect of sulodexide on endothelial glycocalyx and vascular permeability in patients with type 2 diabetes mellitus. Diabetologia. 2010;53:2646–2655. PubMed PMC

Urbanek T, Zbigniew K, Begier-Krasinska B, Baum E, Breborowicz A. Sulodexide suppresses inflammation in patients with chronic venous insufficiency. Int Angiol. 2015;34:589–596. PubMed

Urbanek T, Krasinski Z, Suminska-Jasinska K, et al. Sulodexide reduces the inflammatory reaction and senescence of endothelial cells in conditions involving chronic venous disease. Int Angiol. 2016;35:140–147. PubMed

Coccheri S, Scondotto G, Agnelli G, Aloisi D, Palazzini E, Zamboni V. Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers. Thromb Haemost. 2002;87:947–952. PubMed

Coccheri S, Bignamini AA. Pharmacological adjuncts for chronic venous ulcer healing. Phlebology. 2016;31:366–367. PubMed PMC

Wu B, Lu J, Yang M, Xu T. Sulodexide for treating venous leg ulcers. Cochrane Database Syst Rev. 2016;6:CD010694. PubMed PMC

Gonzalez Ochoa A. Sulodexide and phlebotonics in the treatment of venous ulcer. Int Angiol. 2017;36:82–87. PubMed

Schwarzer G. meta: an R package for meta-analysis. R News. 2007;7:40–45.

R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2017;18:https://www.R-project.org/. Accessed 22 Apr 2019.

Anon. Section 16.1.3.2 Imputing standard deviations for changes from baseline. In: Higgins JPT, Green S (Ed.). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org; 2011. Accessed 23 Apr 2019.

Dunlap WP, Cortina JM, Vaslow JB, Burke MJ. Meta-analysis of experiments with matched groups or repeated measures designs. Psychol Methods. 1996;1:170–177.

Algina J, Keselman HJ. Approximate confidence intervals for effect sizes. Educ Psychol Meas. 2003;63:537–553.

Ferrero S. Therapy of lower limbs phlebopathies with sulodexide. Clinical study of efficacy and tolerability. NAM. 1990;6:169–172.

Colombo F, Cristadoro F, Troyer L, Varini F. Superficial phlebopathies: tolerability and efficacy of the drug sulodexide. Geriatrics. 1991;8:45–48.

Ganassin L, Sogaro F. Galeazzi E [Evaluation of anti-thrombophilic properties of heparan sulfate in venous vascular pathology. A controlled clinical study versus active reference] Minerva Cardioangiol. 1991;39:275–283. PubMed

Pecis C, Giovilli M, Mezzanotte C, Pecis A, Sgroi G: Complementarity of the medical therapy in the surgical treatment of the varicose disease. Flebolinfologia. 1991; 3.4–3.6 (Article in Italian).

Petruzzellis V, Troccoli T, Florio T, Vadalà P. Sulodexide oral administration: therapeutic activity in chronic venous insufficiency. Giorn It Angiol. 1991;9:139–143.

Luttichau U, Palazzini E. Pharmacological treatment of post-phlebitic syndromes with sulodexide. Med Prax. 1992;13:1–2.

Marabotto M, Cavaliere P. Open trial on a new oral formulation of sulodexide for the treatment of post-phlebitic syndrome. Biol Med. 1992;14:1–12.

Rovere V, Amerio A, Mauro M, et al. Efficacy of action and tolerability of a new oral formulation of sulodexide in the treatment of the post-phlebitic syndrome. Controlled study vs. subcutaneous heparin. Nuova Stampa Med Ital. 1992;12:25–35.

Allegra C. Current role of glycosaminoglycans and perspectives in therapy. Minerva Angiol. 1993;18:45–49.

Saviano M, Maleti O, Liguori L. Double-blind, double-dummy, randomized, multi-centre clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency. Curr Med Res Opin. 1993;13:96–108. PubMed

Verardi S, Ippoliti A, Ramundo A, Ranucci A, Tozzi A. Medium-term treatment of chronic venous insufficiency with oral sulodexide. Agg Med Chir. 1993;11:230–240.

Di Domenica M. Superficial veins thrombosis and varicophlebitides: antithrombotic therapy with sulodexide. Minerva Cardioangiol. 2000;48:152–154.

Flota-Cervera LF, Paz-Janeiro JL, Guevara-Saldívar MI, et al. Sulodexide in chronic venous disease. Clinical experience in Mexico. Rev Mex Angiol. 2014;42:28–37.

Elleuch N, Zidi H, Bellamine Z, Hamdane A, Guerchi M, Jellazi N. Sulodexide in patients with chronic venous disease of the lower limbs: clinical efficacy and impact on quality of life. Adv Ther. 2016;33:1536–1549. PubMed PMC

Bogachev VI, Golovanova OV, Malysheva IN. Efficacy of sulodexide in treatment of chronic venous insufficiency. Results of the ACCORD trial. Angiol Sosud Khir. 2017;23:83–88. PubMed

Flota Cervera LF, Frati Munari AC, Velazquez Herrera AE, Carbajal Contreras A. Chronic venous disease treated with sulodexide: a survey among primary care physicians in Mexico. Int Angiol. 2017;36:558–564. PubMed

Guevara-Saldívar MI, Garza-Ruiz AF, Gonzáles-Ochoa A, et al. Sulodexide for the management of chronic venous disease in clinical stages C3 and C4 Open observational study. Rev Mex Angiol. 2017;17(45):15–22.

Serra R, Gallelli L, Conti A, et al. The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs. Drug Des Devel Ther. 2014;8:519–527. PubMed PMC

Chupin AV, Katorkin SE, Katel’nitskii II, et al. Sulodexide in treatment of chronic venous insufficiency. Results of the All-Russian multicenter programme ACVEDUCT. Angiol Sosud Khir. 2018;24:47–55. PubMed

Ligi D, Croce L, Mosti G, Raffetto JD, Mannello F. Chronic venous insufficiency: transforming growth factor-beta isoforms and soluble endoglin concentration in different states of wound healing. Int J Mol Sci. 2017;18:2206. PubMed PMC

Andreozzi GM. Role of sulodexide in the treatment of CVD. Int Angiol. 2014;33:255–262. PubMed

Frati Munari AC. Medical significance of endothelial glycocalyx. Part 2: its role in vascular diseases and in diabetic complications. Arch Cardiol Mex. 2014;84:110–116. PubMed

Rodríguez Jiménez OA, Frati-Munari A. Varices and chronic venous disease. General aspects and bases for treatment. Galenus. 2014;42:34–37.

Roztocil K, Antignani PL. Sulodexide: it is time for a program against chronic venous disease. Internat Angiol. 2014;33:209–211. PubMed

Frati-Munari AC. Medical significance of endothelial glycocalyx. Arch Cardiol Mex. 2013;83:303–312. PubMed

Mannello F, Medda V, Ligi D, Raffetto JD. Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol. 2013;11:354–365. PubMed

González Ochoa A. Reducing hyperpigmentation after sclerotherapy using an antithrombotic drug. In: Greenhalgh RM, editor. Vascular and endovascular controversies update—40 years of looking forward. London: BIBA Publishing; 2018. pp. 491–496.

Mazzaccaro D, Muzzarelli L, Modafferi A, Righini PC, Settembrini AM, Nano G. Use of venoactive drugs after surgery for varicose veins: a preliminary study. Int Angiol. 2018;37:79–84. PubMed

Zakharova NO, Bulgakova SV, Katorkin SE, Melnikov MA, Treneva EV, Nikolaeva AV. The treatment of elderly and senile patients with venous trophic ulcers and type 2 diabetes mellitus. Adv Gerontol. 2017;30:917–924. PubMed

Apollonio A, Antignani PL, Di Salvo M, et al. A large Italian observational multicentre study on vascular ulcers of the lower limbs (Studio Ulcere Vascolari) Int Wound J. 2016;13:27–34. PubMed PMC

Stoiko YM, Gudymovich VG, Tsyplyashchuk AV. Current aspects of endothelial protection in treatment of patients with chronic venous insufficiency at the stage of trophic disorders. Angiol Sosud Khir. 2016;22:109–114. PubMed

Flota-Cervera LF, Nuricumbo-Vázquez A, Santana-Vega D, et al. Sulodexide for the venous leg ulcers: experience in Mexico. Rev Mex Angiol. 2015;43:131–137.

Katorkin SE. Significance of endothelial protection in treatment of patients with class c6 chronic venous disease and type 2 diabetes mellitus. Angiol Sosud Khir. 2015;21(99–102):4–6. PubMed

Katorkin SE. The evaluation of the effectiveness of the application of sulodexide for the combined treatment of the patients presenting with trophic ulcers on the lower extremities of venous etiology. Flebogiya. 2015;9:35–41.

Zou YX, Feng X, Jing ZP. Efficacy and safety of sulodexide in the treatment of venous ulcers of leg. Pharm Care Res. 2007;7:22–24.

Gacka M, Mastej K, Adamiec R. Thrombotic and fibrinolytic activity in patients with venous ulcer during sulodexide treatment. Przeglad Flehologiczny. 2004;12:97–100.

Mastej K, Gacka M, Adamiec R. Assessment of the healing of venous leg ulcer in post-thrombotic syndrome during combined therapy sulodexide. Przeglad Flehologiczny. 2004;12:131–134.

Kucharzewski M, Franek A, Koziolek H. Treatment of venous leg ulcers with sulodexide. Phlebologie. 2003;32:115–120.

Scondotto G, Aloisi D, Ferrari P, Martini L. Treatment of venous leg ulcers with sulodexide. Angiology. 1999;50:883–889. PubMed

Aldrett E, Frati A. Sulodexide as and adjunctive management in patients with venous leg ulcers. Internat Angiol. 2018;37:73.

Casoni P, Villa F, Corona P. Sulodexide therapy after endovascular or hemodynamic treatment for varicose veins. Internat Angiol. 2018;37:73.

Gossetti B, Irace L, Benedetti-Valentini F. Use of glucosaminoglycans (GAG) in vascular surgery: assumption and clinical experience. Minerva Angiol. 1993;18:41–43.

Stagnaro-Neri M, Stagnaro S. Free radicals and microcirculatory alterations in the cinstitutional hypotonic phlebopathies. Minerva Angiol. 1993;18:105–108.

Cospite M, Ferrara F, Cospite V, Palazzini E. Sulodexide and the microcirculatory component in microphlebopathies. Curr Med Res Opin. 1992;13:56–60. PubMed

Cospite M, Milio G, Ferrara F, Cospite V, Palazzini E. Haemodynamic effects of sulodexide in post-thrombophlebitic syndrome. Phlebologie. 1992;2:733–735.

Mauro M, Ferraro G, Palmieri G. Profibrinolytic and antithrombotic effects of sulodexide oral administration: a double-blind, crossover, placebo-controlled study. Curr Ther Res. 1992;51:342–350.

Del Guercio R, Siciliano G, Niglio A, Del Guercio M. Evaluations on the use of sulodexide in a group of patients with CVI. Minerva Angiol. 1991;16:141–142.

Di Stefano D, Vinci M. Antithrombotic therapy of phlebopathies with sulodexide. Controlled study of efficacy and tolerability. Eur Rev Med Pharmacol Sci. 1989;11:507–515.

Apollonio A, Antignani PL, Di Salvo M, et al. Epidemiology and healing of vascular ulcers in Italy. Preview of the SUV study results (AIUC September 2012): short report. Acta Phlebol. 2012;13:101–103.

Apollonio A, Antignani PL, Di Salvo M, et al. SUV2012. First results of the observational multicenter AIUC study for the epidemiology and treatment investigation of vascular ulcers of the lower limbs in Italy. Acta Vulnol. 2012;10:259–264.

Pecis C, Sgroi G, Giovilli M, Stringhi E, Mezzanotte C. Place of medical therapy with sulodexide in the operated patient with varicose veins. Flebolinfologia. 1990;16:51–53.

Apollonio A, Mosti G, Ricci E. Microcirculation and venous ulcers. Acta Vulnol. 2008;6:125–132.

Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon(R)) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebo-controlled trials. Int Angiol. 2018;37:143–154. PubMed

Sulodexide for Diabetic-Induced Disabilities: A Systematic Review and Meta-Analysis

Zobrazit více v PubMed

figshare
10.6084/m9.figshare.11590920